Herceptin dödsfall

Side Effects of Herceptin: What You Need to Know

Side effects explained

Learn more about some of the side effects Herceptin may cause.

Risk of heart issues

Herceptin has a boxed warning about the risk of cardiac side effects (heart issues). Boxed warnings are the most serious warnings from the Food and Drug Administration (FDA).

Heart issues Herceptin may cause can include heart damage that isn’t reversible. Herceptin’s heart-related side effects may even be fatal.

While heart issues were not common in Herceptin’s studies, examples that were reported include:

Symptoms can vary depending on the exact heart issue, but some general symptoms include:

These heart issues can require long-term treatment with medication.

What might help

Your doctor will order tests to check your heart health before and during your Herceptin treatment. If the results of these tests show heart issues, they will either prescribe drugs or other treatments for these issues or stop your Herceptin treatment.

If you develop any of the symptoms listed above while using Herceptin, contact your doctor immediately.

Risk of infusion reactions or lung issues

Herceptin is given as an intravenous (IV) in

Trastuzumab

Medication

Not to be confused with Trastuzumab emtansine.

Pharmaceutical compound

Trastuzumab Fab region (cyan) binding HER2/neu (gold)

TypeWhole antibody
SourceHumanized (from mouse)
TargetHER2/neu
Trade namesHerceptin, Herceptin SC
Biosimilarstrastuzumab-anns,[1] trastuzumab-dkst,[2] trastuzumab-dttb,[3] trastuzumab-pkrb, trastuzumab-qyyp,[4] trastuzumab-strf,[5] Adheroza,[6] Hercessi,[5] Herzuma,[7][8][9] Herwenda,[10][11] Kanjinti,[1][12][13] Ogivri,[2][14] Ontruzant,[3][15][16] Trastucip,[17] Trazimera,[4] Tuznue,[18][19] Tuzucip,[17] Zercepac[20][21]
AHFS/Monograph
MedlinePlusa
License data
Pregnancy
category
Routes of
administration		Intravenous, subcutaneous
Drug classAntineoplastic agent
ATC code
Legal status
MetabolismUnknown, possibly reticuloendothelial system
Elimination half-life days
CAS Number
PubChem
  • herceptin dödsfall

    • 25 Years of Trastuzumab: A Legacy of Innovation

    The AACR Annual Meeting , held April , commemorated several milestones, including the 25th anniversary of the approval of the blockbuster breast cancer drug trastuzumab (Herceptin).

    Coincidentally, Lisa Coussens, PhD, MD (hc), FAACR, FAIO, who closed out her begrepp as AACR President during the meeting, played a significant role in the story of trastuzumab. In , as a postdoctoral fellow in the lab of Axel Ullrich, PhD, FAACR, Coussens and colleagues cloned the gene HER2, which encoded a fängelse surface receptor that could drive fängelse growth and proliferation. A few years later, researchers discovered that overexpression of HER2 drove the growth of breast tumors.

    One solution was to stymie the progression of cancers that express the HER2 receptor with the antibody trastuzumab, which blocks the function of HER2.

    “The impact of trastuzumab has been huge. It changed drug upptäckt in pharma and biotech,” said, H. Michael Shepard, PhD, president, Chief Executive Officer, and Chief Scientific Officer of Enosi Therapeutics, during the Annual Meeting session honoring the anniversary of trastuzumab’s approval. “This program created the current